IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Herpes Simplex Type II | Drug: TDF Drug: Placebo Vaginal Gel Drug: Vaginal TFV Gel Drug: Placebo Tablets | Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double Blind (Participant, Care Provider, Investigator) Primary Purpose: Treatment |
| Official Title: | Effect of Tenofovir on Genital HSV Shedding: a Randomized, Double-blind, Placebo-controlled Clinical Trial |
- HSV Shedding Rate in Those Receiving Oral TDF, Vaginal TFV, or Double Placebo [ Time Frame: Comparison of 4 weeks of treatment phase with 4 weeks of lead-in phase ]The within-person changes in rate of HSV shedding during study drug administration (treatment phase) compared with the rate of HSV shedding during lead-in observation phase in the same participants. We evaluated only weeks 2-5 of HSV shedding during the treatment phase in comparison with the 4 weeks of the lead-in phase. We excluded the first week of samples from the treatment phase in order to allow for physiologic run-in of the treatment. This is analyzed separately for each treatment arm and not compared between arms.
- Within-person Changes in Log-copy Numbers of HSV [ Time Frame: Comparison of 4 weeks of treatment phase with 4 weeks of lead-in phase ]
The within-person changes in mean log-copy numbers of HSV shed during treatment phase (oral TDF, vaginal TFV, or double placebo) compared with the lead-in (observation) phase in the same participants. Each treatment arm is analyzed separately without comparison between arms.
We evaluated only weeks 2-5 of HSV shedding during the treatment phase in comparison with the 4 weeks of the lead-in phase. We excluded the first week of samples from the treatment phase in order to allow for physiologic run-in of the treatment.
- Genital Lesion Rate [ Time Frame: Comparison of 4 weeks of treatment phase with 4 weeks of lead-in phase ]
The within person change in proportion of days with lesions between the lead-in (observational) and study drug (treatment) phase for each arm separately. No between arm comparisons were performed. We include intent to treat with all randomized participants as well as per protocol (persons receiving study drug for at least 30 days with 90% or better reported compliance per returned product counts).
We evaluated only weeks 2-5 of HSV shedding during the treatment phase in comparison with the 4 weeks of the lead-in phase. We excluded the first week of samples from the treatment phase in order to allow for physiologic run-in of the treatment.
- Asymptomatic Shedding (Shedding on Days Without Genital Lesions) [ Time Frame: Comparison of 4 weeks of treatment phase with 4 weeks of lead-in phase ]
Within person changes in shedding on days without lesions between the lead-in (observational) phase and the study drug (treatment) phase. Each arm is evaluated separately and no inter arm comparisons are made.
We evaluated only weeks 2-5 of HSV shedding during the treatment phase in comparison with the 4 weeks of the lead-in phase. We excluded the first week of samples from the treatment phase in order to allow for physiologic run-in of the treatment.
| Enrollment: | 73 |
| Study Start Date: | February 2012 |
| Study Completion Date: | June 2015 |
| Primary Completion Date: | June 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
No Intervention: Run-in Phase
Women will first participate in a run-in phase with twice daily swabbing.
|
|
|
Experimental: Study Drug Phase: TDF
Participants will take tenofovir disoproxil fumarate (TDF) tablets and apply a placebo vaginal gel. Participants will begin treatment and swab the genital region twice daily for 5 more weeks. Study drugs will be administered once daily.
|
Drug: TDF
Oral tenofovir will be administered as tablets. TDF (Viread®) tablets contain 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
Other Name: Tenofovir disoproxil fumarate (TDF) oral tablets
Drug: Placebo Vaginal Gel
Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible. The placebo gel (known as the 'universal' placebo gel) is formulated to minimize any possible effects — negative or positive — on study endpoints. Other Name: Placebo gel
|
|
Experimental: Study Drug Phase: Vaginal TFV Gel
Participants will take oral placebo tablets and apply a tenofovir 1% (TFV) vaginal gel. Participants will begin treatment and swab the genital region twice daily for 5 more weeks. Study drugs will be administered once daily.
|
Drug: Vaginal TFV Gel
Tenofovir 1% gel (w/w) is a gel formulation of tenofovir. Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.
Other Name: Tenofovir 1% Vaginal Gel
Drug: Placebo Tablets
TDF placebo tablets are film-coated and contain denatonium benzoate, a bittering agent, in addition to other inactive ingredients. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
Other Name: Oral placebo
|
|
Placebo Comparator: Study Drug Phase: Double Placebo
Participants will take oral placebo tablets and apply a placebo vaginal gel. Participants will begin treatment and swab the genital region twice daily for 5 more weeks. Study drugs will be administered once daily.
|
Drug: Placebo Vaginal Gel
Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible. The placebo gel (known as the 'universal' placebo gel) is formulated to minimize any possible effects — negative or positive — on study endpoints. Other Name: Placebo gel
Drug: Placebo Tablets
TDF placebo tablets are film-coated and contain denatonium benzoate, a bittering agent, in addition to other inactive ingredients. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
Other Name: Oral placebo
|
Detailed Description:
Eligibility| Ages Eligible for Study: | 18 Years to 50 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Women age 18-50
- HSV-2 seropositive by the University of Washington (UW) Western blot
- History of recurrent genital herpes, with more than 4 recurrences but less than 10 in the last year or, if currently on suppressive therapy, with more than 4 recurrences but less than 10 in the year prior to starting suppressive therapy
- HIV negative
- General good health
- Willing to not use antiviral therapy (other than the study drug) for the duration of the study
- Willing to obtain a swab from genital secretions twice daily for the duration of the study
- Willing to use effective birth control
- Able to provide written informed consent at screening and enrollment
Exclusion Criteria:
- HIV positive or at high risk for HIV acquisition (intravenous drug user or HIV+ sex partner)
- Hepatitis B (HepB) antigen (Ag) positive, or at high risk for HepB acquisition and not vaccinated
- Have a history of adverse reaction to tenofovir and/or adefovir
- Immunosuppressive medications, except for intranasal or topical (not high potency) steroids.
- Any kidney disease, or renal insufficiency, defined as serum creatinine >1.5 mg/dl. Participants with a prior history of a single episode of pyelonephritis will be eligible.
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times upper limit of normal
- Pregnancy, as confirmed by a urine pregnancy test, planning to become pregnant during the course of the trial, or breast-feeding.
- Serious medical conditions or active infections
- Any other conditions that in the judgment of the investigator would preclude successful completion of the clinical trial.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT01448616
| United States, Washington | |
| University of Washington Virology Research Clinic | |
| Seattle, Washington, United States, 98104 | |
| Principal Investigator: | Anna Wald, MD, MPH | University of Washington |
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Anna Wald, Professor, University of Washington |
| ClinicalTrials.gov Identifier: | NCT01448616 History of Changes |
| Other Study ID Numbers: |
41250-J |
| Study First Received: | September 14, 2011 |
| Results First Received: | August 5, 2015 |
| Last Updated: | December 2, 2015 |
Additional relevant MeSH terms:
|
Herpes Simplex Herpesviridae Infections DNA Virus Infections Virus Diseases Skin Diseases, Viral Skin Diseases, Infectious Skin Diseases Tenofovir |
Antiviral Agents Anti-Infective Agents Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Retroviral Agents Anti-HIV Agents |
ClinicalTrials.gov processed this record on June 22, 2017